scholarly article | Q13442814 |
P50 | author | Crystal Watson | Q91334881 |
P2093 | author name string | Machaon M K Bonafede | |
Kathleen M Fox | |||
Shravanthi R Gandra | |||
Nicole Princic | |||
P2860 | cites work | Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up | Q46389803 |
The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. | Q50639396 | ||
Psoriasis: epidemiology, clinical features, and quality of life | Q24675003 | ||
Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data | Q31116692 | ||
Epidemiology of spondyloarthritis in North America | Q34717134 | ||
A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs | Q35638528 | ||
Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists | Q37085249 | ||
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics | Q37142442 | ||
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population | Q37484466 | ||
Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice | Q45159990 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
adalimumab | Q348260 | ||
P304 | page(s) | 234-248 | |
P577 | publication date | 2012-03-09 | |
P1433 | published in | Advances in Therapy | Q4686392 |
P1476 | title | Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis | |
P478 | volume | 29 |
Q36942901 | Analysis and Breakdown of Overall 1-Year Costs Relative to Inpatient and Outpatient Care Among Rheumatoid Arthritis Patients Treated with Biotherapies Using Health Insurance Claims Database in Alsace |
Q33572758 | Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends |
Q57169149 | Biosimilars: Review of current applications, obstacles, and their future in medicine |
Q37452967 | Comparing Biologic Cost Per Treated Patient Across Indications Among Adult US Managed Care Patients: A Retrospective Cohort Study |
Q53119214 | Comparing biologic persistence and healthcare costs in rheumatoid arthritis patients initiating subcutaneous biologics. |
Q36942874 | Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic |
Q34211985 | Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population |
Q37583028 | Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea. |
Q37453002 | Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil |
Q36274355 | Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis |
Q38068578 | Emerging drugs for axial spondyloarthritis including ankylosing spondylitis |
Q38166016 | Emerging drugs for the treatment of uveitis |
Q51039528 | Funding a smoking cessation program for Crohn's disease: an economic evaluation. |
Q41122444 | Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease. |
Q36576535 | Hepatotoxicity Associated with the Use of Anti-TNF-α Agents |
Q37284234 | Pharmacogenomics in clinical practice and drug development |
Q91918289 | Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece |
Q58563236 | Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis |
Q40942139 | The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use. |
Q38207916 | Treatment of psoriasis: focus on clinic-based management with infliximab |